At a June UNGA meeting, Russia refused to support a consensus political declaration on ending the HIV/AIDS epidemic. What does this mean for the future of HIV/AIDS and international politics?
Read in the Washington Post
Our partners at Fundación Huésped in Argentina describe how they use the HIVPL to monitor whether countries are delivering on their policy commitments.Read more
The American Academy of HIV Medicine featured the HIVPL’s 2020 Global HIV Policy Report in a special issue of its magazine.Read more
The Global AIDS Strategy 2021-2026 sets an ambitious new set of targets, the 10-10-10 targets, calling on countries to repeal punitive laws/policies that target key populations and to implement right-supportive laws/policies that combat stigma, discrimination, and gender-based violence.
These targets will not be achieved without transparency, evidence, and accountability—transparency around the laws/policies that countries have in place, evidence to show why policy change is necessary and beneficial, and advocacy to hold governments accountable for acting on the commitments they made at the 2021 UN High-Level Meeting on HIV/AIDS and achieving the 10-10-10 targets.Read more
The science of HIV has never been better, but policy too often gets in the way of a robust HIV response. The HIV Policy Lab is a comprehensive database to monitor, track, and compare national HIV policies across countries. The HIV Policy Lab data and visualization tools examine whether science-based policies have been implemented at the national level in 194 countries. This video provides an overview of the HIV Policy Lab and features leaders in the fight against HIV discussing how it can be used.
On World AIDS Day last month, a breakthrough was announced for children with HIV in low-income countries. The integrase inhibitor dolutegravir, an antiretroviral medicine recommended for first-line treatment, is being manufactured in a 10- milligram formulation that can be given easily to infants weighing less than 20 kilograms. It dissolves in liquid and tastes like strawberries, and the price negotiated with generic drug companies Viatris and Macleods Pharmaceuticals is competitive. Following this announcement, the Global Fund to Fight AIDS, Tuberculosis and Malaria; the United States President's Emergency Plan...Read more
The state of the science around ending HIV has never been better, but slow translation of scientific advances into laws and policies is a major barrier to progress in the fight against HIV. Laws and policies drive who has access to the benefits of science, how people living with and affected by HIV are treated, how health systems are structured, and how officials engage with communities. This report presents the state of HIV policy in countries around the world in 2020. Drawing on data from the HIV Policy Lab, it tracks which countries have adopted 33 key HIV-related laws and policies recommended by UNAIDS and WHO and which have...Read more
Law and policy differences help explain why, as HIV-related science has advanced swiftly, some countries have realised remarkable progress on AIDS while others see expanding epidemics. We describe the structure and findings of a new dataset and research platform, the HIV Policy Lab, which fills an important knowledge gap by measuring the HIV-related policy environment across 33 indicators and 194 countries over time, with online access and visualisation. Cross-national indicators can be critical tools in international governance-building social power to monitor state behaviour with the potential to change policy and improve domestic...Read more